Breaking: Will Vital Therapies Inc Short Squeeze Soon?

Breaking: Will Vital Therapies Inc Short Squeeze Soon?

The stock of Vital Therapies Inc (NASDAQ:VTL) is a huge mover today! About 150,743 shares traded hands or 206.87% up from the average. Vital Therapies Inc (NASDAQ:VTL) has declined 29.14% since April 8, 2016 and is downtrending. It has underperformed by 34.79% the S&P500.
The move comes after 7 months negative chart setup for the $188.02M company. It was reported on Nov, 10 by Barchart.com. We have $4.76 PT which if reached, will make NASDAQ:VTL worth $20.68 million less.

Vital Therapies Inc (NASDAQ:VTL) Ratings Coverage

Out of 6 analysts covering Vital Therapies Inc (NASDAQ:VTL), 2 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 33% are positive. Vital Therapies Inc has been the topic of 10 analyst reports since August 7, 2015 according to StockzIntelligence Inc. BTIG Research downgraded Vital Therapies Inc (NASDAQ:VTL) on Monday, October 26 to “Neutral” rating. The stock of Vital Therapies Inc (NASDAQ:VTL) has “Buy” rating given on Monday, August 24 by Canaccord Genuity. Credit Suisse reinitiated Vital Therapies Inc (NASDAQ:VTL) on Monday, August 10 with “Outperform” rating. SunTrust downgraded the shares of VTL in a report on Monday, August 24 to “Buy” rating. On Friday, August 7 the stock rating was initiated by BTIG Research with “Buy”. Suntrust Robinson downgraded the stock to “Neutral” rating in Tuesday, September 29 report. The stock of Vital Therapies Inc (NASDAQ:VTL) earned “Neutral” rating by SunTrust on Tuesday, September 29. On Monday, August 24 the stock rating was downgraded by William Blair to “Outperform”. The firm has “Neutral” rating given on Monday, August 24 by Suntrust Robinson. The rating was downgraded by Credit Suisse on Monday, August 24 to “Neutral”.

According to Zacks Investment Research, “Vital Therapies, Inc. is a biotherapeutic company. It is focused on developing a cell-based therapy targeting the treatment of acute liver failure. The Company operates in the United States, Europe, and China. Vital Therapies, Inc. is based in San Diego, California.”

Insitutional Activity: The institutional sentiment increased to 1.58 in 2016 Q2. Its up 0.13, from 1.45 in 2016Q1. The ratio is positive, as 8 funds sold all Vital Therapies Inc shares owned while 11 reduced positions. 7 funds bought stakes while 23 increased positions. They now own 8.18 million shares or 10.33% less from 9.13 million shares in 2016Q1.
State Street Corporation has invested 0% of its portfolio in Vital Therapies Inc (NASDAQ:VTL). Parametric Assoc Ltd Liability Corp has invested 0% of its portfolio in Vital Therapies Inc (NASDAQ:VTL). Voya Investment Management Ltd Liability has 0% invested in the company for 11,533 shares. Blackrock Advsr Ltd holds 0% or 11,350 shares in its portfolio. Creative Planning holds 0% of its portfolio in Vital Therapies Inc (NASDAQ:VTL) for 633 shares. Nationwide Fund Advsr holds 0% or 14,423 shares in its portfolio. Price T Rowe Md accumulated 0% or 17,900 shares. The Arizona-based Ironwood Financial Limited has invested 0% in Vital Therapies Inc (NASDAQ:VTL). Proshare Advsr Ltd Limited Liability Company reported 26,157 shares or 0% of all its holdings. Morgan Stanley has 3,251 shares for 0% of their US portfolio. Wells Fargo And Mn has 8,021 shares for 0% of their US portfolio. Deutsche National Bank & Trust Ag owns 7,356 shares or 0% of their US portfolio. Fifth Third Commercial Bank has 0% invested in the company for 3,000 shares. Moreover, Goldman Sachs Grp Inc has 0% invested in Vital Therapies Inc (NASDAQ:VTL) for 91,375 shares. Intl holds 0% of its portfolio in Vital Therapies Inc (NASDAQ:VTL) for 13,632 shares.

Insider Transactions: Since August 11, 2016, the stock had 1 insider purchase, and 0 sales for $699,999 net activity. $699,999 worth of shares were bought by Hasnain Faheem on Thursday, August 11.

More important recent Vital Therapies Inc (NASDAQ:VTL) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on April 16, 2014, also Globenewswire.com published article titled: “Vital Therapies Announces Third Quarter Financial Results”, Quotes.Wsj.com published: “News Vital Therapies Inc.VTL” on November 24, 2013. More interesting news about Vital Therapies Inc (NASDAQ:VTL) was released by: Globenewswire.com and their article: “Vital Therapies Receives FDA Guidance; Announces Upcoming Launch of VTL-308 …” with publication date: November 19, 2015.

VTL Company Profile

Vital Therapies, Inc., incorporated on January 13, 2004, is a biotherapeutic company. The Firm is focused on developing a human hepatic cell treatment targeting acute forms of liver failure. The Company’s product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Firm initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company’s ELAD System consists of approximately four disposable ELAD C3A cell cartridges containing its human liver-derived C3A cells attached to a reusable delivery device using customized disposable tubing sets. The delivery device is based on a cardio-pulmonary bypass machine, which it has configured for the ELAD System treatment. This unit and customized disposable sets are attached to the ELAD C3A cell cartridges where the patient’s blood plasma is treated by its VTL C3A cells before being returned to the patient. Treatment will generally consist of a single session of continuous allogeneic cellular therapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment